18F-FLUC-CEST PET/MR in Patients With Brain Mets

Launched by UNIVERSITY OF WISCONSIN, MADISON · Nov 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to see if there are tumors in the brains of people who have brain metastasis, which means cancer has spread to the brain from another part of the body. The researchers want to find out if a special type of imaging called PET/MRI can detect cancerous tissue better than other imaging methods. Participants in this study will have a PET/MRI scan that takes about three hours and will help doctors learn more about their condition.

To be eligible for this trial, participants must be at least 18 years old, have a diagnosis of brain metastasis with at least one visible tumor on a recent MRI, and have received radiation therapy in the past two years. They should also be currently or recently treated with other cancer therapies. It's important that participants can lie still for 30-60 minutes during the scan. If you're considering joining this study, you should know that you'll need to provide consent, and certain health conditions or allergies could prevent you from participating.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older
• • Able and willing to provide informed consent
• • Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI
• • Received radiation therapy at some point in the last 2 years
• • Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy, immunotherapy, or chemotherapy following radiation therapy.
• • Patients are eligible for the study if their most recent standard-of-care MRI, used to assess disease location and extent, raises the question of tumor recurrence versus treatment-related changes. This concern can be noted by the radiologist or other members of the multidisciplinary care team, such as during a multidisciplinary conference. Additionally, if there are clinical concerns based on evolving exam findings or symptoms, and the treating physician suspects progression versus treatment-induced changes, the patient is also eligible for the study.
• • Be able to lie still for 30-60 minutes during the imaging procedure
• • Willing and able to undergo PET/MRI
• * Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
• • The subject has their own prescription for the medication
• • The informed consent process is conducted prior to the self-administration of this medication
• • They come to the research visit with a driver
• Exclusion Criteria:
• • Subject unable or unwilling to provide informed consent
• • Subject is pregnant
• • Subject with contraindication(s) to or inability to undergo a PET or MRI
• • Known allergy to 18F-Fluciclovine or any of its excipients